Viridian Therapeutics, Inc. Common Stock (VRDN)

Price$14.68

Favorite Metrics

Price vs S&P 500 (26W)-38.20%

Price vs S&P 500 (4W)-54.99%

Market Capitalization$1.50B

All Metrics

Book Value / Share (Quarterly)$7.09

P/TBV (Annual)2.17x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)242.07%

Cash Flow / Share (Quarterly)$-2.72

Price vs S&P 500 (YTD)-56.76%

Gross Margin (TTM)2.36%

Net Profit Margin (TTM)-483.57%

EPS (TTM)$-4.00

10-Day Avg Trading Volume2.62M

EPS Excl Extra (TTM)$-4.00

Revenue Growth (5Y)132.18%

EPS (Annual)$-4.04

ROI (Annual)-42.49%

Gross Margin (Annual)2.76%

Net Profit Margin (5Y Avg)-35120.44%

Cash / Share (Quarterly)$8.59

Revenue Growth QoQ (YoY)83.33%

ROA (Last FY)-38.09%

Revenue Growth TTM (YoY)23359.93%

EBITD / Share (TTM)$-4.30

ROE (5Y Avg)-43.32%

Operating Margin (TTM)-512.91%

Cash Flow / Share (Annual)$-2.72

P/B Ratio2.08x

P/B Ratio (Quarterly)4.11x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)19.37x

Net Interest Coverage (TTM)-324.65x

ROA (TTM)-50.39%

EPS Incl Extra (Annual)$-4.04

Current Ratio (Annual)12.65x

Quick Ratio (Quarterly)12.37x

3-Month Avg Trading Volume1.94M

52-Week Price Return11.80%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$6.49

P/S Ratio (Annual)21.18x

Asset Turnover (Annual)0.08x

52-Week High$34.29

Operating Margin (5Y Avg)-38169.46%

EPS Excl Extra (Annual)$-4.04

CapEx CAGR (5Y)65.39%

Tangible BV CAGR (5Y)59.30%

26-Week Price Return-31.31%

Quick Ratio (Annual)12.37x

13-Week Price Return-55.56%

Total Debt / Equity (Annual)0.12x

Current Ratio (Quarterly)12.65x

Enterprise Value$1,372.195

Revenue / Share Growth (5Y)23.16%

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-24.33%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)12.35x

Pretax Margin (Annual)-483.57%

Cash / Share (Annual)$8.59

3-Month Return Std Dev90.15%

Gross Margin (5Y Avg)13.95%

Net Income / Employee (TTM)$-1

ROE (Last FY)-47.44%

Net Interest Coverage (Annual)-334.48x

EPS Basic Excl Extra (Annual)$-4.04

Receivables Turnover (TTM)2.02x

Total Debt / Equity (Quarterly)0.12x

EPS Incl Extra (TTM)$-4.00

Receivables Turnover (Annual)5.92x

ROI (TTM)-55.01%

P/S Ratio (TTM)21.18x

Pretax Margin (5Y Avg)-35120.44%

Revenue / Share (Annual)$0.84

Tangible BV / Share (Annual)$9.56

Price vs S&P 500 (52W)-22.83%

Year-to-Date Return-52.83%

5-Day Price Return-3.36%

EPS Normalized (Annual)$-4.04

ROA (5Y Avg)-38.35%

Net Profit Margin (Annual)-483.57%

Month-to-Date Return-24.95%

Cash Flow / Share (TTM)$-5.09

EBITD / Share (Annual)$-4.30

Operating Margin (Annual)-512.91%

LT Debt / Equity (Annual)0.12x

ROI (5Y Avg)-41.54%

LT Debt / Equity (Quarterly)0.12x

EPS Basic Excl Extra (TTM)$-4.00

P/TBV (Quarterly)3.02x

P/B Ratio (Annual)4.11x

Inventory Turnover (TTM)12.40x

Pretax Margin (TTM)-483.57%

Book Value / Share (Annual)$7.09

Price vs S&P 500 (13W)-57.94%

Beta0.91x

Revenue / Share (TTM)$0.75

ROE (TTM)-58.44%

52-Week Low$11.76

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.25

4.24

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
VRDNViridian Therapeutics, Inc. Common Stock	21.18x	23359.93%	2.36%	—	$14.68
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Viridian Therapeutics is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease. Its lead candidate, Veligrotug, is a humanized monoclonal antibody targeting IGF-1R, available in both intravenous and subcutaneous formulations.